Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Celltrion Signs Deal with Hungary's Egis Pharmaceuticals to Sell Biosimilars In Former Soviet Republic Countries, Eastern Europe

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Celltrion has signed a deal with Hungary's Egis Pharmaceuticals to sell Celltrion's future biosimilar products in the former Soviet Republic countries and Eastern Union

You may also be interested in...



Deals Of The Week’s Takeaway From PSA: Optimism With Aches

The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.

Servier Offers $483 Million To Buy Rest Of Hungarian Generics Maker Egis

After holding a 51% stake in Egis for 18 years, France's mid-sized pharma company Servier is now offering nearly $483 million to buy the rest of the Hungarian generics company.

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel